Recombinant Human IKBKG Protein

Recombinant human IKBKG protein, also known as NEMO (NF-κB Essential Modulator), is a key regulatory component of the NF-κB signaling pathway, which controls immune responses, inflammation, and cell survival. IKBKG functions as a scaffold protein within the IκB kinase (IKK) complex, linking upstream signals to the activation of NF-κB transcription factors. Structurally, it contains a N-terminal kinase-binding domain, a coiled-coil domain for oligomerization, and a C-terminal zinc finger domain critical for protein interactions and signaling fidelity.

Mutations in the *IKBKG* gene are associated with severe immune deficiencies, such as X-linked anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID), and incontinentia pigmenti (IP), a neurocutaneous disorder. These conditions highlight IKBKG's role in maintaining immune homeostasis and developmental processes. Recombinant IKBKG is often produced in expression systems like *E. coli* or mammalian cells for functional studies, enabling researchers to dissect molecular mechanisms, screen therapeutic compounds, or explore disease-related variants in vitro.

Its applications extend to investigating NF-κB dysregulation in cancers, autoimmune diseases, and infections. Recombinant IKBKG also serves as a critical tool for structural biology and developing targeted therapies to modulate inflammatory pathways.